A Phase I Dose-Escalation Study of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Oral Dose of Tigulixostat
Jun Tao, Shuaibing Liu, Ruijuan Liu, Wenhua Xue, Suke Sun, Suyun Wang, Chunjie Sun, Yidong Li, Chengzeng Wang, Xin Tian · 2025
Read A Phase I Dose-Escalation Study of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Oral Dose of Tigulixostat by Jun Tao, Shuaibing Liu, Ruijuan Liu, Wenhua Xue, Suke Sun, Suyun Wang, Chunjie Sun, Yidong Li, Chengzeng Wang, Xin Tian (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12707156.txt.
Description
Jun Tao and co-authors run a first-in-human dose test of a gout drug pick in a 2025 study. The drug, tigulixostat, blocks an enzyme that makes uric acid. High uric acid drives gout and joint pain. Thirty healthy adults in China took one dose each, in steps from 25 to 300 milligrams. Blood and urine tests tracked the drug and its main break-down form.
Drug levels rose in step with dose across the full range. Uric acid in blood fell by 13 to 29 percent in one day, with bigger drops at high doses. The gain leveled off near the top dose. No grave side effects showed up, and all reported effects were mild. The team read the drug as well behaved and dose-true. The pick now moves to longer tests in people with high uric acid.
Catalog record
| CREATOR | Jun Tao, Shuaibing Liu, Ruijuan Liu, Wenhua Xue, Suke Sun, Suyun Wang, Chunjie Sun, Yidong Li, Chengzeng Wang, Xin Tian |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |